AHR agonist 10 

AHR agonist 10 (B19) is a potent AHR agonist (EC₅₀ = 2.01 nM). AHR agonist 10 can elevate the transcript levels of key AHR downstream pathway target genes, including CYP1A1 and CYP1B1. AHR agonist 10 can downregulate the expression levels of CD36, IL-18 and shows low cytotoxicity (>40 μM) to normal cells. AHR agonist 10 can suppress the expression of CCL5, CCL20, IL-6, IL-8, S100A9, TLR4, TNF-α, and TNFR1, demonstrating that AHR agonist 10 effectively modulate inflammatory responses through AHR dependent signaling pathways. AHR agonist 10 can be used for psoriasis research^[1].

AHR agonist 10 (10 μM, 20 μM, 24 h) can effectively enhance the expression levels of CYP1A1 and CYP1B1 in the AHR knockdown HaCaT cells^[1].
AHR agonist 10 (5 μM) can suppress the expression on the mRNA level of CYP1A1, CYP1B1, CCL5, CCL20, IL-6, IL-8, S100A9, TLR4, TNF-α, and TNFR1 on the Lipopolysaccharides (HY-D1056) (LPS)-induced HaCaT cell^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

AHR agonist 10 (1%, topical application, once daily, 7 days) inhibits the onset and progression of Imiquimod (HY-B0180)-induced psoriasis symptoms on the mice’s backs, marked by reduced erythema and scaling^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

284.35

C₁₈H₂₀O₃

1191937-43-5

CC(C1=C(C=C(C=C1O)/C=C/C2=CC=C(C=C2)OC)O)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhao Y, et al. Design, Optimization, and Biological Evaluation of Novel Tapinarof Analogues as AHR Agonists for Topical Psoriasis Treatment. J Med Chem. 2025 Sep 25;68(18):19249-19268.  [Content Brief]